

DHS Clinical Policy Updates – Obesity Treatment Agents, GLP-1s, and DPP-4 Inhibitors

On November 24, 2025, the Pennsylvania Department of Human Services (DHS) issued updates to clinical policies regarding **Obesity Treatment Agents, GLP-1 receptor agonists, and DPP-4 inhibitors**.

These documents outline revised medical necessity criteria and confirm the exclusion of GLP-1 agents for obesity coverage. For your convenience, the newly released DHS bulletins are linked below and can also be found by using the [DHS Bulletin Search](#).

Please review these updates thoroughly and ensure familiarity with the new requirements, as they are critical for prescribing compliance.

- [Prior Authorization of Obesity Treatment Agents – Pharmacy Services](#)
- [Coverage Change and Prior Authorization of GLP-1 Receptor Agonists \(Formerly Hypoglycemics, Incretin Mimetics/Enhancers and Obesity Treatment Agents\) – Pharmacy Services](#)
- [Prior Authorization of Hypoglycemics, DPP-4 Inhibitors \(Formerly Hypoglycemics, Incretin Mimetics/Enhancers\) – Pharmacy Services](#)

If you have questions or concerns regarding this updates you may contact the PHW pharmacy team at: PharmacyEscalationsPHW@Centene.com or please reach out to your Provider Representative directly.

Thank you for your continued partnership in serving PA's CHC Participants.

PA Health & Wellness